Rhythm Pharmaceuticals Inkomsten in het verleden

We zijn nog bezig met het verwerken van het laatste winstrapport van dit bedrijf

Verleden criteriumcontroles 0/6

De winst van Rhythm Pharmaceuticals is gedaald met een gemiddeld jaarlijks percentage van -16.5%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 19%. De inkomsten zijn groeide met een gemiddeld percentage van 80.7% per jaar.

Belangrijke informatie

-16.5%

Groei van de winst

-4.3%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	80.7%
Rendement op eigen vermogen	-144.5%
Nettomarge	-256.2%
Volgende winstupdate	05 Nov 2024

Recente prestatie-updates uit het verleden

Recent updates

Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)

Jun 12

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

May 09

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon

May 05

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Mar 03

Rhythm Pharmaceuticals: Action Too Specific

Feb 23

Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Jan 08

We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely

Nov 03

We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate

Jul 23

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing

Jun 17

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

May 05

Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans

Apr 01

An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued

Dec 15

We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully

Oct 24

Rhythm Pharmaceuticals: Revisiting The Investment Thesis

Oct 10

Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours

Sep 14

Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS

Sep 06

Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts

Aug 08

Rhythm Pharmaceuticals Q2 2022 Earnings Preview

Aug 01

Rhythm Pharma gains as NICE recommends obesity drug

Jul 18

Opbrengsten en kosten

Hoe Rhythm Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGM:RYTM Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	102	-261	134	222
31 Mar 24	92	-274	127	226
31 Dec 23	77	-185	118	135
30 Sep 23	62	-186	111	129
30 Jun 23	44	-182	103	116
31 Mar 23	34	-181	95	114
31 Dec 22	24	-181	92	109
30 Sep 22	17	-181	87	117
30 Jun 22	13	-176	82	123
31 Mar 22	5	-166	75	117
31 Dec 21	3	-70	68	104
30 Sep 21	1	-62	61	95
30 Jun 21	0	-60	54	90
31 Mar 21	0	-56	48	88
31 Dec 20	0	-134	46	90
30 Sep 20	0	-132	42	93
30 Jun 20	0	-134	42	97
31 Mar 20	0	-146	42	109
31 Dec 19	0	-141	37	109
30 Sep 19	0	-133	36	103
30 Jun 19	0	-115	34	88
31 Mar 19	0	-87	31	61
31 Dec 18	0	-74	28	50
30 Sep 18	0	-59	24	38
30 Jun 18	0	-53	18	33
31 Mar 18	0	-47	13	30
31 Dec 17	0	-38	10	23
30 Sep 17	0	-36	8	22
30 Jun 17	0	-32	7	21
31 Mar 17	0	-30	6	21
31 Dec 16	0	-29	6	20
30 Sep 16	0	-27	6	18
30 Jun 16	0	-23	6	14
31 Mar 16	0	-17	5	10
31 Dec 15	0	-12	3	7
30 Sep 15	0	-6	2	4
30 Jun 15	0	-3	1	2
31 Mar 15	0	-5	1	4
31 Dec 14	0	-6	1	5

Kwaliteitswinsten: RYTM is momenteel verliesgevend.

Groeiende winstmarge: RYTM is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: RYTM is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 16.5% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van RYTM over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: RYTM is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( -2.3% ).

Rendement op eigen vermogen

Hoge ROE: RYTM heeft een negatief Return on Equity ( -144.53% ), omdat het momenteel verliesgevend is.

Rhythm Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Rhythm Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Rhythm Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Rhythm Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Rhythm Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Recent updates

Rhythm Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?

Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck

Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for Imcivree® (Setmelanotide) in Patients as Young as 2 Years Old

Rhythm Pharmaceuticals, Inc. Announces European Commission Expands IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

Rhythm Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Rhythm Pharmaceuticals, Inc. Announces Appointment of Alastair Garfield, as Chief Scientific Officer

Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Index

Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients Between 2 and 6 Years Old with Bardet Biedl Syndrome

Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)

New minor risk - Profitability

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

Rhythm Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Executive VP & Head of North America notifies of intention to sell stock

Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals

Consensus EPS estimates fall by 14%, revenue upgraded

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Consensus EPS estimates fall by 61%

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Rhythm Pharmaceuticals: Action Too Specific

Rhythm Pharmaceuticals, Inc. Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

Chief Technical Officer notifies of intention to sell stock

New minor risk - Profitability

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Price target increased by 9.0% to US$53.78

Price target increased by 10% to US$52.67

Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Forecast to breakeven in 2026

Chief Technical Officer notifies of intention to sell stock

Price target increased by 7.8% to US$47.67

CFO & Treasurer exercised options and sold US$860k worth of stock

Price target increased by 8.4% to US$44.22

CFO & Treasurer notifies of intention to sell stock

Chief Technical Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)

We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely

Rhythm Pharmaceuticals, Inc. Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome

Executive VP & Head of North America exercised options and sold US$180k worth of stock

Executive VP & Head of North America notifies of intention to sell stock

Consensus revenue estimates increase by 28%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 19%

We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate

Rhythm Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Rhythm Pharmaceuticals, Inc. Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing

Rhythm Pharmaceuticals, Inc. Announces Approval of IMCIVREE®? Setmelanotide Solution for Weight Management in Adult and Pediatric Patients

Consensus EPS estimates fall by 10%

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans

Full year 2022 earnings released: US$3.48 loss per share (vs US$1.40 loss in FY 2021)

Price target increased by 8.6% to US$36.56

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued

Rhythm Pharmaceuticals Announces ?Imcivree (Setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Price target increased to US$33.44

Price target increased to US$33.00

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind